Covaxin booster increases neutralising antibodies, study finds
The Hindu
The control arm of the study had 93 participants and the intervention arm had 91 participants, but most of these people were under 55 years
A joint study by Bharat Biotech and ICMR has provided the first evidence of the immune response of a homologous booster six months after the second dose. The randomised control trial was carried out on 184 participants belonging to the phase-2 trial arm that received 6 microgram of the vaccine for both first and second dose.
The booster dose was found to be safe. The most frequent adverse events reported were mild and transient pain and itching at the injection site.
The booster dose was given seven months (215 days) after the second dose. The primary outcome was to measure neutralising antibody titres four weeks after the booster shot.
Gaganyaan-G1, the first of three un-crewed test missions that will lead up to India’s maiden human spaceflight, is designed to mimic - end to end - the actual flight and validate critical technologies and capabilities including the Human-rated Launch Vehicle Mark-3 (HLVM3), S. Unnikrishnan Nair, Director, Vikram Sarabhai Space Centre (VSSC), has said